News headlines about Bioanalytical Systems (NASDAQ:BASI) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a news impact score of 0.16 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.0872548159154 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media stories that may have impacted Accern’s analysis:

Bioanalytical Systems (NASDAQ:BASI) opened at 1.82 on Tuesday. The stock has a 50 day moving average price of $1.74 and a 200-day moving average price of $1.43. The stock’s market cap is $14.90 million. Bioanalytical Systems has a 52 week low of $0.60 and a 52 week high of $2.42.

Bioanalytical Systems (NASDAQ:BASI) last announced its earnings results on Monday, May 15th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $6.36 million during the quarter. Bioanalytical Systems had a negative net margin of 8.95% and a negative return on equity of 29.32%. On average, equities analysts anticipate that Bioanalytical Systems will post $0.01 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at

About Bioanalytical Systems

Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Stock Ratings for Bioanalytical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems Inc. and related stocks with our FREE daily email newsletter.